Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.78 below Xencor Inc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 166 other companies have achieved higher Quick Ratio than Xencor Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 728, from total ranking in the second quarter 2026 at 2174.

Explain Quick Ratio?
How much Cash & cash equivalents XNCR�s has?
What are XNCR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/XNCR/financial-strength

https://api.csimarket.com/api/v1/companies/XNCR/fundamentals

https://api.csimarket.com/api/v1/companies/XNCR/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

XNCR Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-11.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	110.75 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.78	Subscribe	Subscribe	Subscribe	Subscribe
XNCR's Total Ranking	# 728	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-6.84 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-87.74 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 167
Healthcare Sector	# 270
Overall Market	# 728

Quick Ratio Statistics
High	Average	Low
34.73	5.57	0.19
(Mar 31 2018)		(Mar 31 2026)

Financial Statements
Xencor Inc's Current Liabilities	$ 76 Millions	Visit XNCR's Balance sheet
Xencor Inc's Cash & cash equivalent	$ 60 Millions	Visit XNCR's Balance sheet
Source of XNCR's Sales		Visit XNCR's Sales by Geography

Cumulative Xencor Inc's Quick Ratio

XNCR's Quick Ratio for the trailling 12 Months

XNCR Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-8.3 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	295.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.88	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4052	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-3.03 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	5.36 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to XNCR Financial Strength Comparisons >> Go to Compare XNCR Quick Ratio to its Competitors

On the trailing twelve months basis XNCR Cash & cash equivalent more than doubled by 110.75 % in Q3 2026 year on year, while Current Liabilities decreased to $76 millions, this led to increase in in Xencor Inc's Quick Ratio to 1.88, above XNCR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Xencor Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 3940 to 4052.

Explain Quick Ratio?
How much Cash & cash equivalents XNCR�s has?
What are XNCR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 440
Healthcare Sector	# 903
Within the Market	# 4052

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.39	1.19	0.12
(Mar 31 2015)		(Mar 31 2017)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Maravai Lifesciences Holdings Inc	2.14	$ 73.023 Millions	$ 34.160 Millions
Ernexa Therapeutics Inc	2.13	$ 5.575 Millions	$ 2.614 Millions
Madrigal Pharmaceuticals Inc	2.12	$ 962.387 Millions	$ 454.244 Millions
Puma Biotechnology Inc	2.09	$ 108.575 Millions	$ 51.971 Millions
Corcept Therapeutics Inc	2.09	$ 370.703 Millions	$ 177.675 Millions
Dianthus Therapeutics Inc	1.95	$ 55.686 Millions	$ 28.515 Millions
Xeris Biopharma Holdings Inc	1.95	$ 262.164 Millions	$ 134.479 Millions
Ars Pharmaceuticals Inc	1.95	$ 138.354 Millions	$ 70.995 Millions
Lite Strategy Inc	1.92	$ 4.281 Millions	$ 2.234 Millions
Mineralys Therapeutics Inc	1.91	$ 101.273 Millions	$ 53.075 Millions
Amarin Corp Plcuk	1.85	$ 323.379 Millions	$ 175.136 Millions
Mustang Bio inc	1.80	$ 14.276 Millions	$ 7.947 Millions
Biovie Inc	1.78	$ 7.733 Millions	$ 4.350 Millions
Alnylam Pharmaceuticals Inc	1.74	$ 3,587.255 Millions	$ 2,063.006 Millions
Insmed Inc	1.73	$ 1,146.626 Millions	$ 662.181 Millions
Nkarta Inc	1.72	$ 48.354 Millions	$ 28.072 Millions
Mannkind Corporation	1.67	$ 181.525 Millions	$ 108.524 Millions
Verastem Inc	1.67	$ 172.801 Millions	$ 103.328 Millions
Agios Pharmaceuticals Inc	1.66	$ 128.549 Millions	$ 77.588 Millions
Bridgebio Pharma Inc	1.57	$ 1,538.855 Millions	$ 977.237 Millions
Arcutis Biotherapeutics Inc	1.51	$ 259.460 Millions	$ 172.357 Millions
Regeneron Pharmaceuticals Inc	1.50	$ 9,301.100 Millions	$ 6,202.100 Millions
Emergent Biosolutions Inc	1.44	$ 175.700 Millions	$ 122.000 Millions
Compass Pathways Plc	1.36	$ 443.979 Millions	$ 325.863 Millions
Sarepta Therapeutics Inc	1.34	$ 878.776 Millions	$ 656.353 Millions
Zai Lab Limited	1.32	$ 559.658 Millions	$ 424.249 Millions
Urogen Pharma Ltd	1.31	$ 96.901 Millions	$ 74.031 Millions
Ani Pharmaceuticals Inc	1.28	$ 420.758 Millions	$ 328.717 Millions
Vertex Pharmaceuticals Inc	1.26	$ 6,303.300 Millions	$ 5,000.300 Millions
Nature s Sunshine Products inc	1.22	$ 89.377 Millions	$ 73.488 Millions

Date modified: 2026-11-06T12:57:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.